NCT05932862 - A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

429

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

January 3, 2029

Study Completion Date

August 3, 2029

Conditions

Advanced Solid Tumor

Interventions

DRUG

XL309

XL309 will be administered orally per assigned schedule.

DRUG

Olaparib

Olaparib will be administered orally per assigned schedule.

Trial Locations (16)

10029

RECRUITING

Exelixis Clinical Site #5, New York

32224

RECRUITING

Exelixis Clinical Site #15, Jacksonville

32827

RECRUITING

Exelixis Clinical Site #8, Orlando

33612

RECRUITING

Exelixis Clinical Site #16, Tampa

37203

RECRUITING

Exelixis Clinical Site #6, Nashville

38138

RECRUITING

Exelixis Clinical Site #11, Germantown

44106

RECRUITING

Exelixis Clinical Site #7, Cleveland

55905

RECRUITING

Exelixis Clinical Site #14, Rochester

64111

WITHDRAWN

Exelixis Clinical Site #10, Kansas City

73104

RECRUITING

Exelixis Clinical Site #13, Oklahoma City

77030

RECRUITING

Exelixis Clinical Site #1, Houston

WITHDRAWN

Exelixis Clinical Site #2, Houston

78229

RECRUITING

Exelixis Clinical Site #3, San Antonio

78758

RECRUITING

Exelixis Clinical Site #4, Austin

92708

WITHDRAWN

Exelixis Clinical Site #12, Fountain Valley

08901

RECRUITING

Exelixis Clinical Site #9, New Brunswick